inflammatory rheumatic diseases, biologic agents, targeted synthetic DMARD, safety, efficacy, dose reduction strategy
Conditions
Interventions
none
Sponsors
Reade Rheumatology, Amsterdam
Eligibility
Inclusion criteria
Inclusion criteria: - Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis/non-radiographic axial spondyloarthritis, according to the treating rheumatologist; - Written informed consent.
Exclusion criteria
Exclusion criteria: None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy will be determined in comparison to baseline by comparing disease activity, patient reported outcomes, radiological progression and functional capacity during follow-up. Safety will be determined by the occurrence of side effects. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in (bio)markers during treatment will be analyzed versus baseline. | — |
Contacts
Public ContactM.T. Nurmohamed
Jan van Breemen Research Institute | Reade Postbus 58271
Outcome results
None listed